Panigrahy Ashok, Jakacki Regina I, Pollack Ian F, Ceschin Rafael, Okada Hideho, Nelson Marvin D, Kohanbash Gary, Dhall Girish, Bluml Stefan
Department of Radiology, UPMC Children's Hospital of Pittsburgh, 4401 Penn Ave Floor 2, Pittsburgh, PA 15224, USA.
Department of Hematology Oncology, UPMC Children's Hospital of Pittsburgh, 4401 Penn Ave Floor 9, Pittsburgh, PA 15224, USA.
Cancers (Basel). 2022 Dec 5;14(23):5995. doi: 10.3390/cancers14235995.
Diffuse intrinsic pontine gliomas (DIPG) are highly aggressive tumors with no currently available curative therapy. This study evaluated whether measurements of in vivo cell metabolites using magnetic resonance spectroscopy (MRS) may serve as biomarkers of response to therapy, including progression.
Single-voxel MR spectra were serially acquired in two cohorts of patients with DIPG treated with radiation therapy (RT) with or without concurrent chemotherapy and prior to progression: 14 participants were enrolled in a clinical trial of adjuvant glioma-associated antigen peptide vaccines and 32 patients were enrolled who did not receive adjuvant vaccine therapy. Spearman correlations measured overall survival associations with absolute metabolite concentrations of myo-inositol (mI), creatine (Cr), and -acetyl-aspartate (NAA) and their ratios relative to choline (Cho) during three specified time periods following completion of RT. Linear mixed-effects regression models evaluated the longitudinal associations between metabolite ratios and time from death (terminal decline).
Overall survival was not associated with metabolite ratios obtained shortly after RT (1.9-3.8 months post-diagnosis) in either cohort. In the vaccine cohort, an elevated mI/Cho ratio after 2-3 doses (3.9-5.2 months post-diagnosis) was associated with longer survival (rho = 0.92, 95% CI 0.67-0.98). Scans performed up to 6 months before death showed a terminal decline in the mI/Cho ratio, with an average of 0.37 ratio/month in vaccine patients (95% CI 0.11-0.63) and 0.26 (0.04-0.48) in the non-vaccine cohort.
Higher mI/Cho ratios following RT, consistent with less proliferate tumors and decreased cell turnover, were associated with longer survival, suggesting that this ratio can serve as a biomarker of prognosis following RT. This finding was seen in both cohorts, although the association with OS was detected earlier in the vaccine cohort. Increased mI/Cho (possibly reflecting immune-effector cell influx into the tumor as a mechanism of tumor response) requires further study.
弥漫性脑桥内在型胶质瘤(DIPG)是极具侵袭性的肿瘤,目前尚无治愈性疗法。本研究评估了使用磁共振波谱(MRS)测量体内细胞代谢物是否可作为治疗反应(包括疾病进展)的生物标志物。
在两组接受放射治疗(RT)(有或无同步化疗)且处于疾病进展前的DIPG患者中,连续采集单体素MR波谱:14名参与者参加了辅助性胶质瘤相关抗原肽疫苗的临床试验,32名未接受辅助疫苗治疗的患者入组。Spearman相关性分析测量了放疗结束后三个特定时间段内,总生存期与肌醇(mI)、肌酸(Cr)和N-乙酰天门冬氨酸(NAA)的绝对代谢物浓度及其相对于胆碱(Cho)的比率之间的关联。线性混合效应回归模型评估了代谢物比率与死亡时间(终末期下降)之间的纵向关联。
在两个队列中,放疗后不久(诊断后1.9 - 3.8个月)获得的代谢物比率与总生存期均无关联。在疫苗队列中,2 - 3剂疫苗接种后(诊断后3.9 - 5.2个月)mI/Cho比率升高与更长的生存期相关(rho = 0.92,95%CI 0.67 - 0.98)。在死亡前6个月内进行的扫描显示mI/Cho比率呈终末期下降,疫苗组患者平均每月下降0.37(95%CI 0.11 - 0.63),非疫苗队列患者平均每月下降0.26(0.04 - 0.48)。
放疗后较高的mI/Cho比率与肿瘤增殖减少和细胞更新率降低一致,与更长的生存期相关,表明该比率可作为放疗后预后的生物标志物。两个队列均观察到这一发现,尽管在疫苗队列中更早检测到与总生存期的关联。mI/Cho升高(可能反映免疫效应细胞流入肿瘤作为肿瘤反应机制)需要进一步研究。